Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3228021 | 1.00 | SIGMAR1 (0.53) | SIGMAR1CHRM1CHRM3CHRM5CHRM2 | |
| SCHEMBL3210424 | 0.84 | GLA (0.54) | CHRM1CHRM3CHRM5CHRM2CHRNA7 | |
| SCHEMBL3210416 | 0.84 | GLA (0.54) | CHRM1CHRM3CHRM5CHRM2CHRNA7 | |
| SCHEMBL3216580 | 0.78 | CYP1A2 (0.54) | SIGMAR1CHRM1CHRM3CHRM5CHRM2 | |
| SCHEMBL3219330 | 0.78 | MEN1 (0.51) | CHRM1CHRM3CHRM5CHRM2CHRNA7 | |
| SCHEMBL3216566 | 0.78 | CYP1A2 (0.54) | SIGMAR1CHRM1CHRM3CHRM5CHRM2 | |
| SCHEMBL3219324 | 0.78 | MEN1 (0.51) | CHRM1CHRM3CHRM5CHRM2CHRNA7 | |
| SCHEMBL8988424 | 0.78 | CHRNA7 (0.51) | CHRM1CHRM3CHRM5CHRM2CHRNA7 | |
| SCHEMBL3218557 | 0.77 | CHRNA7 (0.58) | CHRM1CHRM3CHRM5CHRM2CHRNA7 | |
| SCHEMBL3206387 | 0.77 | CHRNA7 (0.58) | CHRM1CHRM3CHRM5CHRM2CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056565-A1 | Heterocyclic Derivatives as M3 Muscarinic Receptors | ARGENTA DISCOVERY LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| EP-2121688-A1 | HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS | Argenta Discovery Ltd (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008099186-A1 | HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS | ARGENTA DISCOVERY LIMITED (GB) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056565-A1 | Heterocyclic Derivatives as M3 Muscarinic Receptors | CHRM2, CHRM3, CHRM1 | SIGMAR1 169/4885CHRM1 3/4885CHRM3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.